Roche and reMYND will make Parkinson's and Alzheimer's drugs

09/7/2010 | Reuters

Roche Holding is collaborating with Belgium's reMYND to develop two of the latter's preclinical compounds, which suppress tau neurotoxicity in Alzheimer's disease and alpha-synuclein neurotoxicity in Parkinson's disease. ReMYND might receive from Roche more than $637 million in milestone fees, plus royalties.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA